CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 865 enrolled
Drug / intervention
Herpes Zoster vaccine GSK 1437173A +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02045836
NCT02045836Phase 3Completed
CompareCT.gov

Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With Pneumovax 23™ in Adults Aged 50 Years and Older

GlaxoSmithKline·interventional·Posted Jan 27, 2014·Updated May 14, 2021

In Brief

A Phase 3 clinical trial evaluating Herpes Zoster vaccine GSK 1437173A and Licensed pneumococcal polysaccharide conjugate vaccine (23-valent, adsorbed), Pneumovax 23™ for Herpes Zoster and Herpes Zoster Vaccine. Completed, enrolled 865 participants across 9 sites in 3 countries.

Detailed Summary

The purpose of this study is to assess the immunogenicity, reactogenicity and safety of the GSK Biologicals HZ/su candidate vaccine when its first dose is co-administered with Pneumovax 23™ vaccine in adults aged 50 years or older.The impact of HZ/su vaccine on Pneumovax 23™ vaccine immune response will also be evaluated.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHerpes Zoster, Herpes Zoster Vaccine
CountriesCanada, Estonia, United States
Collaborators--

Timeline

Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedJan 27, 2014
Enrollment StartMar 5, 2014
Primary CompletionJul 2, 2015
Study CompletionJun 17, 2016
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 12.4 years ago

Interventions

Herpes Zoster vaccine GSK 1437173Abiological

2 doses administered intramuscularly (IM) in the deltoid region of the non-dominant arm.

Licensed pneumococcal polysaccharide conjugate vaccine (23-valent, adsorbed), Pneumovax 23™biological

One dose administered intramuscularly (IM) in the deltoid region of the non-dominant arm.